{{Drugbox
| IUPAC_name = 3-(4-Hexoxy-1,2,5-thiadiazol-3-yl)-1-methyl-5,6-dihydro-2''H''-pyridine
| image = Xanomeline.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 57
| CAS_number = 131986-45-3
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 60809
| ChemSpiderID = 54797
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9ORI6L73CJ
| KEGG = D06330
| ChEMBL = 21536

<!--Chemical data-->
| C=14 | H=23 | N=3 | O=1 | S=1 
| molecular_weight = 281.42 g/mol
| smiles = CCCCCCOC1=NSN=C1C2=CCCN(C2)C
}}

'''Xanomeline''' ('''LY-246,708'''; '''Lumeron''', '''Memcor''') is a [[muscarinic acetylcholine receptor]] [[agonist]] with reasonable [[binding selectivity|selectivity]] for the [[muscarinic acetylcholine receptor M1|M<sub>1</sub>]] and [[muscarinic acetylcholine receptor M4|M<sub>4</sub>]] subtypes,<ref name="pmid8835881">{{cite journal  |vauthors=Farde L, Suhara T, Halldin C, etal | title = PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man | journal = Dementia (Basel, Switzerland) | volume = 7 | issue = 4 | pages = 187–95 | year = 1996 | pmid = 8835881 | doi = | url = }}</ref><ref name="pmid18481916">{{cite journal | vauthors = Jakubík J, Michal P, Machová E, Dolezal V | title = Importance and prospects for design of selective muscarinic agonists | journal = Physiological Research / Academia Scientiarum Bohemoslovaca | volume = 57 Suppl 3 | issue = | pages = S39–47 | year = 2008 | pmid = 18481916 | doi = | url = http://www.biomed.cas.cz/physiolres/pdf/57%20Suppl%203/57_S39.pdf}}</ref><ref name="pmid19111716">{{cite journal | vauthors = Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA | title = Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice | journal = European Journal of Pharmacology | volume = 603 | issue = 1-3 | pages = 147–9 |date=January 2009 | pmid = 19111716 | doi = 10.1016/j.ejphar.2008.12.020 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(08)01252-1}}</ref><ref name="pmid19168056">{{cite journal  |vauthors=Heinrich JN, Butera JA, Carrick T, etal | title = Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists | journal = European Journal of Pharmacology | volume = 605 | issue = 1-3 | pages = 53–6 |date=March 2009 | pmid = 19168056 | doi = 10.1016/j.ejphar.2008.12.044 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(09)00033-8}}</ref> though it is also known to act as a [[muscarinic acetylcholine receptor M5|M<sub>5</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="pmid16002459">{{cite journal | vauthors = Grant MK, El-Fakahany EE | title = Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 315 | issue = 1 | pages = 313–9 |date=October 2005 | pmid = 16002459 | doi = 10.1124/jpet.105.090134 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16002459}}</ref> It has been studied for the treatment of both [[Alzheimer's disease]] and [[schizophrenia]], particularly the [[cognitive]] and [[negative symptom]]s,<ref name="pmid18676593">{{cite journal | vauthors = Lieberman JA, Javitch JA, Moore H | title = Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry | journal = The American Journal of Psychiatry | volume = 165 | issue = 8 | pages = 931–6 |date=August 2008 | pmid = 18676593 | doi = 10.1176/appi.ajp.2008.08050769 | url = http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=18676593}}</ref> although [[gastrointestinal]] [[side effect]]s led to a high drop-out rate in [[clinical trial]]s.<ref name="pmid12212779">{{cite journal | author = Messer WS | title = The utility of muscarinic agonists in the treatment of Alzheimer's disease | journal = Journal of Molecular Neuroscience : MN | volume = 19 | issue = 1-2 | pages = 187–93 | year = 2002 | pmid = 12212779 | doi = 10.1007/s12031-002-0031-5}}</ref><ref name="pmid12847557">{{cite journal | vauthors = Mirza NR, Peters D, Sparks RG | title = Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists | journal = CNS Drug Reviews | volume = 9 | issue = 2 | pages = 159–86 | year = 2003 | pmid = 12847557 | doi = 10.1111/j.1527-3458.2003.tb00247.x| url = }}</ref> Despite this, xanomeline has been shown to have reasonable efficacy for the treatment of schizophrenia symptoms, and one recent human study found robust improvements in verbal [[learning]] and [[short-term memory]] associated with xanomeline treatment.<ref name="pmid18593778">{{cite journal  |vauthors=Shekhar A, Potter WZ, Lightfoot J, etal | title = Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia | journal = The American Journal of Psychiatry | volume = 165 | issue = 8 | pages = 1033–9 |date=August 2008 | pmid = 18593778 | doi = 10.1176/appi.ajp.2008.06091591 | url = http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=18593778}}</ref>

== See also ==
* [[Alvameline]]
* [[Milameline]]
* [[Sabcomeline]]
* [[Tazomeline]]

== References ==
{{Reflist}}

{{Nootropics}}
{{Anti-dementia drugs}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic agonists]]
[[Category:Pyridines]]
[[Category:Thiadiazoles]]